Skip to main content

Table 4 Meta-regression analysis for the associated factors and risk of DF events in patients with SGLT2i treatment

From: SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

Parameter β 95% CI P value Parameter β 95% CI P value
Demographic characteristic
 Age (year old) − 0.089 − 0.192, 0.014 0.087 Sex (male%) − 0.021 − 0.058, 0.016 0.247
 BMI (kg/m2) − 0.001 − 0.060, 0.058 0.920 Diabetes duration (year) − 0.027 − 0.187, 0.133 0.732
HbA1c and weight change
 HbA1c change (%) − 1.723 − 3.749, 0.303 0.091 Weight change (kg)* − 0.476 − 0.836, − 0.116 0.012
 HbA1c change difference (%) 1.305 − 1.289, 3.900 0.307 Weight change difference (kg)* − 0.437 − 0.719, − 0.155 0.004
Hemodynamic indicator
 Baseline SBP (mmHg) 0.023 − 0.085, 0.131 0.660 Baseline DBP (mmHg) 0.201 − 0.364, 0.767 0.458
 SBP change (mmHg) − 0.264 − 0.541, − 0.013 0.060 DBP change (mmHg)* − 0.312 − 0.610, − 0.015 0.041
 Hemoglobin change (g/L) − 0.902 − 2.010, 0.206 0.087 HCT change 0.015 − 1.164, 1.193 0.976
 Volume depletion (event%) − 0.007 − 0.075, 0.061 0.772
Renal function profile
 Baseline eGFR (mL/min/1.73m2) − 0.003 − 0.041, 0.035 0.867 eGFR change (mL/min/1.73m2) − 0.114 − 0.755, 0.527 0.706
PAD risk factor
 Previous PAD (%) − 0.007 − 0.075, 0.061 0.772
  1. *P < 0.05. BMI body mass index, SGLT2i sodium glucose co-transporter 2 inhibitor, PAD peripheral arterial disease, DF diabetic foot, SBP systolic blood pressure, DBP diastolic blood pressure, HCT hematocrit, eGFR estimated glomerular filtration rate